A 60-Year-Old Woman with Later Relapsed/Refractory Multiple Myeloma

Caitlin Costello, MD, presents the case of a 60-year-old woman with later relapsed/refractory multiple myeloma and discusses how the treatment landscape has evolved, highlighting remaining unmet needs.

Following the recent approvals of ide-cel and cilta-cel CAR T-cell therapy for patients with relapsed/refractory multiple myeloma, a hematologist-oncologist discusses clinical research supporting their utilization.

An expert on relapsed/refractory multiple myeloma discusses the role of stem cell transplantation in current treatment paradigms.

Caitlin Costello, MD, provides clinical insights on best practices for treating patients with relapsed/refractory multiple myeloma who receive early-line CAR T-cell therapy and later relapse.

A hematologist-oncologist provides clinical advice to community-based clinicians on key strategies for optimizing the treatment of patients with relapsed/refractory multiple myeloma.

Caitlin Costello, MD, looks to the future of treating patients with relapsed/refractory multiple myeloma, highlighting potential opportunities and challenges in the therapeutic landscape.